Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 21071439 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Carriere A, et al. (2011) ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J Biol Chem 286, 567-77 21071439
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial) [Raptor (human), transfection]
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
phorbol ester no change compared to control
EGF no change compared to control

T202-p - ERK1 (human)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial) [Raptor (human), transfection]
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
phorbol ester increase
U0126 phorbol ester inhibit treatment-induced increase
PD184352 phorbol ester inhibit treatment-induced increase
rapamycin phorbol ester augment treatment-induced increase
HRas (human) increase
insulin no change compared to control
phorbol ester insulin increase
PD184352 insulin no change compared to control
rapamycin insulin no change compared to control

Y204-p - ERK1 (human)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial) [Raptor (human), transfection]
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
phorbol ester increase
U0126 phorbol ester inhibit treatment-induced increase
PD184352 phorbol ester inhibit treatment-induced increase
rapamycin phorbol ester augment treatment-induced increase
HRas (human) increase
insulin no change compared to control
phorbol ester insulin increase
PD184352 insulin no change compared to control
rapamycin insulin no change compared to control

T185-p - ERK2 (human)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial) [Raptor (human), transfection]
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
phorbol ester increase
U0126 phorbol ester inhibit treatment-induced increase
PD184352 phorbol ester inhibit treatment-induced increase
rapamycin phorbol ester augment treatment-induced increase
HRas (human) increase
insulin no change compared to control
phorbol ester insulin increase
PD184352 insulin no change compared to control
rapamycin insulin no change compared to control

Y187-p - ERK2 (human)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial) [Raptor (human), transfection]
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
phorbol ester increase
U0126 phorbol ester inhibit treatment-induced increase
PD184352 phorbol ester inhibit treatment-induced increase
rapamycin phorbol ester augment treatment-induced increase
HRas (human) increase
insulin no change compared to control
phorbol ester insulin increase
PD184352 insulin no change compared to control
rapamycin insulin no change compared to control

S380-p - p90RSK (human)
Orthologous residues
p90RSK (human): S380‑p, p90RSK iso2 (human): S389‑p, p90RSK (mouse): S369‑p, p90RSK iso3 (mouse): , p90RSK (rat): S380‑p, p90RSK (chicken): S398‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial) [Raptor (human), transfection]
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
U0126 phorbol ester inhibit treatment-induced increase
PD184352 phorbol ester inhibit treatment-induced increase

S8-p - Raptor (human)
Orthologous residues
Raptor (human): S8‑p, Raptor (mouse): S8‑p, Raptor (rat): S8‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, mutation of modification site
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  raptor S8/696/863A mutant
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK1 (human)
KINASE ERK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) activation of upstream enzyme, siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme
KINASE ERK2 (human) activation of upstream enzyme, siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
Downstream Regulation
 Comments:  promotes mTORC1 activity and signaling to downstream substrates, such as 4E-BP1

S696-p - Raptor (human)
Orthologous residues
Raptor (human): S696‑p, Raptor (mouse): S696‑p, Raptor (rat): S696‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, mass spectrometry, mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  bone cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), 293 (epithelial) [Raptor (human), transfection], HeLa (cervical), U2OS (bone cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  raptor S8/696/863A mutant
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
KINASE ERK1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) activation of upstream enzyme, siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme
KINASE ERK1 (human) activation of upstream enzyme, siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
U0126 phorbol ester inhibit treatment-induced increase
PD184352 phorbol ester inhibit treatment-induced increase
rapamycin phorbol ester no effect upon treatment-induced increase
siRNA phorbol ester inhibit treatment-induced increase siRNA ERK1/2
EGF increase
siRNA EGF inhibit treatment-induced increase siRNA ERK1/2
insulin no change compared to control
PD184352 insulin no change compared to control
rapamycin insulin no change compared to control
phorbol ester insulin increase
Downstream Regulation
 Comments:  promotes mTORC1 activity and signaling to downstream substrates, such as 4E-BP1

T706-p - Raptor (human)
Orthologous residues
Raptor (human): T706‑p, Raptor (mouse): T706‑p, Raptor (rat): T706‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester no change compared to control
U0126 phorbol ester no change compared to control

S719-p - Raptor (human)
Orthologous residues
Raptor (human): S719‑p, Raptor (mouse): S719‑p, Raptor (rat): S719‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human

S721-p - Raptor (human)
Orthologous residues
Raptor (human): S721‑p, Raptor (mouse): S721‑p, Raptor (rat): S721‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human

S722-p - Raptor (human)
Orthologous residues
Raptor (human): S722‑p, Raptor (mouse): S722‑p, Raptor (rat): S722‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human

S859-p - Raptor (human)
Orthologous residues
Raptor (human): S859‑p, Raptor (mouse): S859‑p, Raptor (rat): S859‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human

S863-p - Raptor (human)
Orthologous residues
Raptor (human): S863‑p, Raptor (mouse): S863‑p, Raptor (rat): S863‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, mass spectrometry, mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  bone cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), 293 (epithelial) [Raptor (human), transfection], HeLa (cervical), U2OS (bone cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  raptor S8/696/863A mutant
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK1 (human)
KINASE ERK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) activation of upstream enzyme, siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme
KINASE ERK2 (human) activation of upstream enzyme, siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
U0126 phorbol ester inhibit treatment-induced increase
PD184352 phorbol ester inhibit treatment-induced increase
rapamycin phorbol ester no effect upon treatment-induced increase
siRNA phorbol ester inhibit treatment-induced increase siRNA ERK1/2
EGF increase
siRNA EGF inhibit treatment-induced increase siRNA ERK1/2
insulin no change compared to control
PD184352 insulin no change compared to control
rapamycin insulin no change compared to control
phorbol ester insulin increase
Downstream Regulation
 Comments:  promotes mTORC1 activity and signaling to downstream substrates, such as 4E-BP1

S877-p - Raptor (human)
Orthologous residues
Raptor (human): S877‑p, Raptor (mouse): S877‑p, Raptor (rat): S877‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester no change compared to control
U0126 phorbol ester no change compared to control

S235-p - S6 (human)
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial) [Raptor (human), transfection]
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
U0126 phorbol ester inhibit treatment-induced increase

S236-p - S6 (human)
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial) [Raptor (human), transfection]
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
U0126 phorbol ester inhibit treatment-induced increase

S240-p - S6 (human)
Orthologous residues
S6 (human): S240‑p, S6 (mouse): S240‑p, S6 (rat): S240‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial) [Raptor (human), transfection]
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
serum increase
phorbol ester increase
PD184352 phorbol ester inhibit treatment-induced increase small decrease
rapamycin phorbol ester inhibit treatment-induced increase small decrease
insulin increase
PD184352 insulin no effect upon treatment-induced increase
rapamycin insulin inhibit treatment-induced increase
phorbol ester insulin augment treatment-induced increase

S244-p - S6 (human)
Orthologous residues
S6 (human): S244‑p, S6 (mouse): S244‑p, S6 (rat): S244‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial) [Raptor (human), transfection]
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
serum increase
phorbol ester increase
PD184352 phorbol ester inhibit treatment-induced increase small decrease
rapamycin phorbol ester inhibit treatment-induced increase small decrease
insulin increase
PD184352 insulin no effect upon treatment-induced increase
rapamycin insulin inhibit treatment-induced increase
phorbol ester insulin augment treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.